Vitamin D5: Difference between revisions
Vitamin D5
No edit summary |
Marked this version for translation |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
<languages /> | |||
<translate> | |||
<!--T:1--> | |||
{{short description|Fat soluble vitamin}}{{DISPLAYTITLE:Vitamin D<sub>5</sub>}} | {{short description|Fat soluble vitamin}}{{DISPLAYTITLE:Vitamin D<sub>5</sub>}} | ||
{{chembox | {{chembox | ||
| Line 43: | Line 46: | ||
[[structural analog|Analogs]] of [[calcitriol]], a form of vitamin D<sub>3</sub>, have been proposed for use as antitumor agents. Studies on vitamin D<sub>3</sub> have shown inhibition of cell proliferation in [[prostate cancer]], but high doses of vitamin D<sub>3</sub> result in [[Hypercalcaemia|hypercalcemia]]. The effects of vitamin D<sub>5</sub> on prostate cancer have also been studied, and unlike vitamin D<sub>3</sub>, vitamin D<sub>5</sub> does not cause [[Hypercalcaemia|hypercalcemia]] while inhibiting tumor cell proliferation. The most researched analogue of vitamin D<sub>5</sub> as an antitumor agent is 1α-hydroxyvitamin D<sub>5.</sub> | [[structural analog|Analogs]] of [[calcitriol]], a form of vitamin D<sub>3</sub>, have been proposed for use as antitumor agents. Studies on vitamin D<sub>3</sub> have shown inhibition of cell proliferation in [[prostate cancer]], but high doses of vitamin D<sub>3</sub> result in [[Hypercalcaemia|hypercalcemia]]. The effects of vitamin D<sub>5</sub> on prostate cancer have also been studied, and unlike vitamin D<sub>3</sub>, vitamin D<sub>5</sub> does not cause [[Hypercalcaemia|hypercalcemia]] while inhibiting tumor cell proliferation. The most researched analogue of vitamin D<sub>5</sub> as an antitumor agent is 1α-hydroxyvitamin D<sub>5.</sub> | ||
=== 1α-Hydroxyvitamin D<sub>5</sub> === | === 1α-Hydroxyvitamin D<sub>5</sub> === <!--T:2--> | ||
<!--T:3--> | |||
1α-Hydroxyvitamin D<sub>5</sub> is a chemical derivative of vitamin D<sub>5</sub>. The motive to study 1α-hydroxyvitamin D<sub>5</sub> as a potential pharmaceutical drug stemmed from the tendency of calcitriol, a natural metabolite produced in the [[kidney]], to cause toxic hypercalcemia in patients when dosed at concentrations needed to interrupt [[prostate cancer]] cells' cycle and stimulate [[apoptosis]]. And while supplementation with [[dexamethasone]] decreases hypercalcemia, bypassing it with an equally effective tumor suppressant would reduce patient cost and stress. Thus, the therapeutic effects of 1α-Hydroxyvitamin D<sub>5</sub> as a potential antitumor agent without the side effects of calcitriol became a topic of study. | 1α-Hydroxyvitamin D<sub>5</sub> is a chemical derivative of vitamin D<sub>5</sub>. The motive to study 1α-hydroxyvitamin D<sub>5</sub> as a potential pharmaceutical drug stemmed from the tendency of calcitriol, a natural metabolite produced in the [[kidney]], to cause toxic hypercalcemia in patients when dosed at concentrations needed to interrupt [[prostate cancer]] cells' cycle and stimulate [[apoptosis]]. And while supplementation with [[dexamethasone]] decreases hypercalcemia, bypassing it with an equally effective tumor suppressant would reduce patient cost and stress. Thus, the therapeutic effects of 1α-Hydroxyvitamin D<sub>5</sub> as a potential antitumor agent without the side effects of calcitriol became a topic of study. | ||
<!--T:4--> | |||
1α-Hydroxyvitamin D<sub>5</sub> was first synthesized in 1997 by researchers in the Department of Chemistry at the [[University of Chicago]], under Robert M. Moriarty and Dragos Albinescu. By 2005, the group had revised its synthesis method for a more streamlined, higher yield-producing route. It involved the photochemical conversion of precursor [[7-Dehydrositosterol|7-dehydrositosteryl]] acetate to contain a conjugated triene system, a hallmark of this analog, followed by [[hydroxylation]], [[photoisomerization]], and [[Protecting group|deprotection]] steps. Their overall yield was 48%. | 1α-Hydroxyvitamin D<sub>5</sub> was first synthesized in 1997 by researchers in the Department of Chemistry at the [[University of Chicago]], under Robert M. Moriarty and Dragos Albinescu. By 2005, the group had revised its synthesis method for a more streamlined, higher yield-producing route. It involved the photochemical conversion of precursor [[7-Dehydrositosterol|7-dehydrositosteryl]] acetate to contain a conjugated triene system, a hallmark of this analog, followed by [[hydroxylation]], [[photoisomerization]], and [[Protecting group|deprotection]] steps. Their overall yield was 48%. | ||
<!--T:5--> | |||
== See also == | == See also == | ||
* [[7-Dehydrositosterol]] | * [[7-Dehydrositosterol]] | ||
* [[Calcipotriene]] | * [[Calcipotriene]] | ||
<!--T:6--> | |||
{{Vitamin}} | {{Vitamin}} | ||
<!--T:7--> | |||
{{二次利用|date=11 December 2023}} | {{二次利用|date=11 December 2023}} | ||
[[Category:Vitamin D]] | [[Category:Vitamin D]] | ||
</translate> | |||